Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2004. The report serves to disclose details regarding the appointment of Dr. Tadataka (Tachi) Yamada to the Board of Directors, effective January 1, 2004, in compliance with the Financial Services Authority's Listing Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding executive appointments and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of Dr. Tadataka Yamada to the Board of Directors. The filing details his current and past directorships and his shareholdings in the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses the disclosure requirements for a new director's appointment and share interests.
Important Facts for Investors
- New Director Appointment: Dr. Tadataka Yamada joined the Board of GlaxoSmithKline plc on January 1, 2004.
- Shareholdings: Dr. Yamada holds an interest in 53,114 Ordinary Share ADRs (representing 106,228 Ordinary Shares).
- Acquisition Timing: 52,930 of the ADRs were acquired prior to his board appointment.
- Options: Dr. Yamada holds options covering 1,205,358 ADRs, all granted prior to his appointment as a director.
- Past Directorships: Dr. Yamada previously served on the boards of SmithKline Beecham p.l.c. and Healtheon/WebMD Corporation.